JAB-23E73 in Adult Participants With Advanced Solid Tumors With KRAS Alteration

This study is to evaluate the safety and tolerability of pan-KRAS inhibitor JAB-23E73 in adult participants with advanced solid tumors

Trial Details

NCT ID
NCT06973564
Phase
PHASE1 / PHASE2
Sponsor
Jacobio Pharmaceuticals Co., Ltd.
Status
RECRUITING
Cancer Type
Colon Cancer Colorectal Cancer
Interventions
  • JAB-23E73
Locations (sample)
  • Rochester, Minnesota, United States|44.02163,-92.4699
  • St Louis, Missouri, United States|38.62727,-90.19789
  • Cleveland, Ohio, United States|41.4995,-81.69541
  • Salt Lake City, Utah, United States|40.76078,-111.89105

Key Eligibility Criteria

  • Written informed consent.
  • Participant must be ≥18 years of age at the time of signing the Informed Consent Form (ICF).
  • Histologically or cytologically confirmed locally advanced or metastatic solid tumors that are not suitable for curative interventions.
  • Patients must have KRAS alterations.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Colon Cancer Colorectal Cancer Trials on Trialify →